WeChat 'Yueya' app support for people on maintenance hemodialysis

Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy

Not applicable Interventional First Affiliated Hospital of Chongqing Medical University · NCT07291154

This project will test whether the 'Yueya' mini-program on WeChat helps people on maintenance hemodialysis follow treatment, feel better, and have fewer complications.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment392 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorFirst Affiliated Hospital of Chongqing Medical University Academic / other
Locations1 site (Chongqing, Chongqing Municipality)
Trial IDNCT07291154 on ClinicalTrials.gov

What this trial studies

This interventional trial randomizes maintenance hemodialysis patients to receive routine care or additional APP-based management delivered via the 'Yueya' mini-program on WeChat, which provides personalized health education, diet and exercise guidance, medication reminders, and condition monitoring. Clinical and laboratory indicators, cardiovascular events, hospitalizations, death, treatment compliance, and patient-reported quality of life will be recorded and compared between groups. The intervention aims to strengthen quality control in the hemodialysis unit and improve individual prognosis through enhanced self-management and clinician oversight. The study is conducted at The First Affiliated Hospital of Chongqing Medical University.

Who should consider this trial

Good fit: Adults 18–75 with stage 5 chronic kidney disease receiving regular maintenance hemodialysis (three times weekly for >3 months), who are relatively stable, able to self-care, and can use WeChat and the 'Yueya' mini-program.

Not a fit: Patients with recent major cardiovascular or cerebrovascular events, severe liver disease, active tuberculosis or AIDS, communication or cognitive barriers, or who cannot or will not use WeChat are unlikely to benefit from this app-based approach.

Why it matters

Potential benefit: If successful, the app-based program could improve treatment adherence, quality of life, and reduce hospitalizations and cardiovascular events for people on maintenance hemodialysis.

How similar studies have performed: Other digital health and app-based interventions in dialysis populations have shown improvements in adherence and quality of life in some trials, but results have been mixed and this specific 'Yueya' approach is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with stage 5 chronic kidney disease, who have received maintenance hemodialysis for more than 3 months, are aged between 18 and 75 years old, and have regular dialysis three times a week.
* Patients with relatively stable condition, who are able to take care of themselves and willing to cooperate with the study.
* Patients who can understand and proficiently use WeChat and the "Yueya" mini - program used in this study.

Exclusion Criteria:

* Patients with communication barriers or other conditions that prevent them from cooperating with the study.
* Patients who have a history of acute myocardial infarction, cerebral infarction or intracerebral hemorrhage in the past six months.
* Patients who are not willing to actively cooperate with the study.
* Patients with severe liver cirrhosis, active tuberculosis and AIDS.

Where this trial is running

Chongqing, Chongqing Municipality

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions End Stage Renal DiseaseMaintenance Hemodialysis
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.